108. SOS: The Rescue from Antibacterial Resistance?
Saturday, October 22, 2011: 8:15 AM-9:45 AM
Room: 104ABC

Learning Objectives:

Upon completion of this session, participants will be able to: 


  • describe novel and off label treatments for difficult to treat and under studied infectious diseases
  • explain the limitations of clinical trials for the study of many infectious diseases

Target Audience: Researchers, Pharmacists, Microbiologists, Investigators, Infectious Diseases Physicians, Infectious Diseases Pediatricians, Fellows-in-Training, Clinicians, Academicians

Tracks: Adult ID

Moderators:  Michael Dudley, PharmD, FIDSA, Mpex Pharmaceuticals and David Andes, MD, University of Wisconsin


8:15 AM

8:45 AM

9:15 AM
New Drugs and Drug Target Development
Michael Dudley, PharmD, FIDSA

CME Credits: CME Pending

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of Pharmacy CE

ACPE Number: 0461-9999-11-118-L01-P


M. Dudley, None

D. Andes, None

D. Hooper, Cubist: Consultant, Consulting fee
Merck: Consultant, Consulting fee
FabPharma: Consultant, Consulting fee
Wockhardt: Consultant, Consulting fee
RibX: Consultant, Consulting fee and Grant recipient

R. Moellering, Jr Jr., Cubist: Consultant, Consulting fee
Pfizer: Consultant, Consulting fee
Forest: Consultant, Consulting fee
Astellas: Consultant, Consulting fee
Merck: Consultant, Consulting fee

M. Dudley, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.